<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 14 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:inherit;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
p.ui-button, li.ui-button, div.ui-button
	{mso-style-name:ui-button;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner, li.ui-spinner, div.ui-spinner
	{mso-style-name:ui-spinner;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-input, li.ui-spinner-input, div.ui-spinner-input
	{mso-style-name:ui-spinner-input;
	margin-top:2.4pt;
	margin-right:16.5pt;
	margin-bottom:2.4pt;
	margin-left:4.8pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden-accessible, li.ui-helper-hidden-accessible, div.ui-helper-hidden-accessible
	{mso-style-name:ui-helper-hidden-accessible;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-buttonset, li.ui-buttonset, div.ui-buttonset
	{mso-style-name:ui-buttonset;
	margin-right:5.25pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker, li.ui-datepicker, div.ui-datepicker
	{mso-style-name:ui-datepicker;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-datepicker-row-break, li.ui-datepicker-row-break, div.ui-datepicker-row-break
	{mso-style-name:ui-datepicker-row-break;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-rtl, li.ui-datepicker-rtl, div.ui-datepicker-rtl
	{mso-style-name:ui-datepicker-rtl;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	direction:rtl;
	unicode-bidi:embed;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu, li.ui-menu, div.ui-menu
	{mso-style-name:ui-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar, li.ui-progressbar, div.ui-progressbar
	{mso-style-name:ui-progressbar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle, li.ui-resizable-handle, div.ui-resizable-handle
	{mso-style-name:ui-resizable-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-n, li.ui-resizable-n, div.ui-resizable-n
	{mso-style-name:ui-resizable-n;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-s, li.ui-resizable-s, div.ui-resizable-s
	{mso-style-name:ui-resizable-s;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-e, li.ui-resizable-e, div.ui-resizable-e
	{mso-style-name:ui-resizable-e;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-w, li.ui-resizable-w, div.ui-resizable-w
	{mso-style-name:ui-resizable-w;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se, li.ui-resizable-se, div.ui-resizable-se
	{mso-style-name:ui-resizable-se;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-sw, li.ui-resizable-sw, div.ui-resizable-sw
	{mso-style-name:ui-resizable-sw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-nw, li.ui-resizable-nw, div.ui-resizable-nw
	{mso-style-name:ui-resizable-nw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-ne, li.ui-resizable-ne, div.ui-resizable-ne
	{mso-style-name:ui-resizable-ne;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectable-helper, li.ui-selectable-helper, div.ui-selectable-helper
	{mso-style-name:ui-selectable-helper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-menu, li.ui-selectmenu-menu, div.ui-selectmenu-menu
	{mso-style-name:ui-selectmenu-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-selectmenu-open, li.ui-selectmenu-open, div.ui-selectmenu-open
	{mso-style-name:ui-selectmenu-open;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-button, li.ui-selectmenu-button, div.ui-selectmenu-button
	{mso-style-name:ui-selectmenu-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider, li.ui-slider, div.ui-slider
	{mso-style-name:ui-slider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-horizontal, li.ui-slider-horizontal, div.ui-slider-horizontal
	{mso-style-name:ui-slider-horizontal;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-vertical, li.ui-slider-vertical, div.ui-slider-vertical
	{mso-style-name:ui-slider-vertical;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-button, li.ui-spinner-button, div.ui-spinner-button
	{mso-style-name:ui-spinner-button;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:6.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip, li.ui-tooltip, div.ui-tooltip
	{mso-style-name:ui-tooltip;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-default, li.ui-state-default, div.ui-state-default
	{mso-style-name:ui-state-default;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus, li.ui-state-focus, div.ui-state-focus
	{mso-style-name:ui-state-focus;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover, li.ui-state-hover, div.ui-state-hover
	{mso-style-name:ui-state-hover;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active, li.ui-state-active, div.ui-state-active
	{mso-style-name:ui-state-active;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight, li.ui-state-highlight, div.ui-state-highlight
	{mso-style-name:ui-state-highlight;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error, li.ui-state-error, div.ui-state-error
	{mso-style-name:ui-state-error;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text, li.ui-state-error-text, div.ui-state-error-text
	{mso-style-name:ui-state-error-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary, li.ui-priority-primary, div.ui-priority-primary
	{mso-style-name:ui-priority-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary, li.ui-priority-secondary, div.ui-priority-secondary
	{mso-style-name:ui-priority-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled, li.ui-state-disabled, div.ui-state-disabled
	{mso-style-name:ui-state-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden, li.ui-helper-hidden, div.ui-helper-hidden
	{mso-style-name:ui-helper-hidden;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-helper-reset, li.ui-helper-reset, div.ui-helper-reset
	{mso-style-name:ui-helper-reset;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-zfix, li.ui-helper-zfix, div.ui-helper-zfix
	{mso-style-name:ui-helper-zfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-overlay, li.ui-widget-overlay, div.ui-widget-overlay
	{mso-style-name:ui-widget-overlay;
	margin-right:0in;
	margin-left:0in;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-clearfix, li.ui-helper-clearfix, div.ui-helper-clearfix
	{mso-style-name:ui-helper-clearfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon, li.ui-icon, div.ui-icon
	{mso-style-name:ui-icon;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-content, li.ui-widget-content, div.ui-widget-content
	{mso-style-name:ui-widget-content;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;}
p.ui-widget-header, li.ui-widget-header, div.ui-widget-header
	{mso-style-name:ui-widget-header;
	margin-right:0in;
	margin-left:0in;
	background:#CCCCCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;
	font-weight:bold;}
p.ui-widget-shadow, li.ui-widget-shadow, div.ui-widget-shadow
	{mso-style-name:ui-widget-shadow;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:-6.0pt;
	margin-bottom:.0001pt;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget, li.ui-widget, div.ui-widget
	{mso-style-name:ui-widget;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-tabs, li.ui-tabs, div.ui-tabs
	{mso-style-name:ui-tabs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog, li.ui-dialog, div.ui-dialog
	{mso-style-name:ui-dialog;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar, li.ui-dialog-titlebar, div.ui-dialog-titlebar
	{mso-style-name:ui-dialog-titlebar;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-ncbiautocomplete-actions, li.ui-ncbiautocomplete-actions, div.ui-ncbiautocomplete-actions
	{mso-style-name:ui-ncbiautocomplete-actions;
	margin-top:.75pt;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#CECECE;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref, li.ui-ncbiautocomplete-link-pref, div.ui-ncbiautocomplete-link-pref
	{mso-style-name:ui-ncbiautocomplete-link-pref;
	margin-right:0in;
	margin-left:0in;
	text-indent:-945.65pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton, li.ui-ncbibutton, div.ui-ncbibutton
	{mso-style-name:ui-ncbibutton;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:inherit;}
p.ui-button-icon-only, li.ui-button-icon-only, div.ui-button-icon-only
	{mso-style-name:ui-button-icon-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icons-only, li.ui-button-icons-only, div.ui-button-icons-only
	{mso-style-name:ui-button-icons-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-outer-div, li.ui-ncbigrid-outer-div, div.ui-ncbigrid-outer-div
	{mso-style-name:ui-ncbigrid-outer-div;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:33.6pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-inner-div, li.ui-ncbigrid-inner-div, div.ui-ncbigrid-inner-div
	{mso-style-name:ui-ncbigrid-inner-div;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-filter-toolbar, li.ui-ncbigrid-filter-toolbar, div.ui-ncbigrid-filter-toolbar
	{mso-style-name:ui-ncbigrid-filter-toolbar;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	line-height:20.25pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar, li.ui-ncbigrid-paged-toolbar, div.ui-ncbigrid-paged-toolbar
	{mso-style-name:ui-ncbigrid-paged-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:19.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-checkbox-toolbar, li.ui-ncbigrid-checkbox-toolbar, div.ui-ncbigrid-checkbox-toolbar
	{mso-style-name:ui-ncbigrid-checkbox-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:21.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-countitems, li.ui-ncbigrid-paged-countitems, div.ui-ncbigrid-paged-countitems
	{mso-style-name:ui-ncbigrid-paged-countitems;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol, li.ui-ncbigrid-paged-pagecontrol, div.ui-ncbigrid-paged-pagecontrol
	{mso-style-name:ui-ncbigrid-paged-pagecontrol;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar-bottom, li.ui-ncbigrid-paged-toolbar-bottom, div.ui-ncbigrid-paged-toolbar-bottom
	{mso-style-name:ui-ncbigrid-paged-toolbar-bottom;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-question, li.ui-ncbigrid-select-question, div.ui-ncbigrid-select-question
	{mso-style-name:ui-ncbigrid-select-question;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbigrid-select-question-footer, li.ui-ncbigrid-select-question-footer, div.ui-ncbigrid-select-question-footer
	{mso-style-name:ui-ncbigrid-select-question-footer;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenu, li.ui-ncbibasicmenu, div.ui-ncbibasicmenu
	{mso-style-name:ui-ncbibasicmenu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenuli, li.ui-ncbibasicmenuli, div.ui-ncbibasicmenuli
	{mso-style-name:ui-ncbibasicmenu>li;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.orientationhortli, li.orientationhortli, div.orientationhortli
	{mso-style-name:orientation_hort>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenu, li.jig-ncbimenu, div.jig-ncbimenu
	{mso-style-name:jig-ncbimenu;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenuli, li.jig-ncbimenuli, div.jig-ncbimenuli
	{mso-style-name:jig-ncbimenu>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbipopper-wrapper, li.ui-ncbipopper-wrapper, div.ui-ncbipopper-wrapper
	{mso-style-name:ui-ncbipopper-wrapper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbipopper-basic, li.ui-ncbipopper-basic, div.ui-ncbipopper-basic
	{mso-style-name:ui-ncbipopper-basic;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#303030;}
p.brieflinkpopdesc, li.brieflinkpopdesc, div.brieflinkpopdesc
	{mso-style-name:brieflinkpopdesc;
	margin-top:4.8pt;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbitoggler-slave, li.ui-ncbitoggler-slave, div.ui-ncbitoggler-slave
	{mso-style-name:ui-ncbitoggler-slave;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbitoggler-slave-open, li.ui-ncbitoggler-slave-open, div.ui-ncbitoggler-slave-open
	{mso-style-name:ui-ncbitoggler-slave-open;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbilinksmenu, li.ui-ncbilinksmenu, div.ui-ncbilinksmenu
	{mso-style-name:ui-ncbilinksmenu;
	margin-right:0in;
	margin-left:0in;
	background:#FCFCFC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#999999;
	font-weight:bold;}
p.ui-ncbilinksmenu-loadingmessage, li.ui-ncbilinksmenu-loadingmessage, div.ui-ncbilinksmenu-loadingmessage
	{mso-style-name:ui-ncbilinksmenu-loadingmessage;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiclearbutton-wrap, li.ui-ncbiclearbutton-wrap, div.ui-ncbiclearbutton-wrap
	{mso-style-name:ui-ncbiclearbutton-wrap;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander, li.ui-ncbiexpander, div.ui-ncbiexpander
	{mso-style-name:ui-ncbiexpander;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander-simple, li.ui-ncbiexpander-simple, div.ui-ncbiexpander-simple
	{mso-style-name:ui-ncbiexpander-simple;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-arrow-bar, li.ui-expander-arrow-bar, div.ui-expander-arrow-bar
	{mso-style-name:ui-expander-arrow-bar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-controllink, li.ui-expander-controllink, div.ui-expander-controllink
	{mso-style-name:ui-expander-controllink;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbiinpagenav-goto-container, li.jig-ncbiinpagenav-goto-container, div.jig-ncbiinpagenav-goto-container
	{mso-style-name:jig-ncbiinpagenav-goto-container;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch, li.ui-ncbisetswitch, div.ui-ncbisetswitch
	{mso-style-name:ui-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.ui-ncbisetswitch-hasstar, li.ui-ncbisetswitch-hasstar, div.ui-ncbisetswitch-hasstar
	{mso-style-name:ui-ncbisetswitch-hasstar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fg-button-icon-left, li.fg-button-icon-left, div.fg-button-icon-left
	{mso-style-name:fg-button-icon-left;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbihistogram, li.jig-ncbihistogram, div.jig-ncbihistogram
	{mso-style-name:jig-ncbihistogram;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram, li.ui-ncbihistogram, div.ui-ncbihistogram
	{mso-style-name:ui-ncbihistogram;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-area, li.ui-ncbihistogram-display-area, div.ui-ncbihistogram-display-area
	{mso-style-name:ui-ncbihistogram-display-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-areaollih3, li.ui-ncbihistogram-display-areaollih3, div.ui-ncbihistogram-display-areaollih3
	{mso-style-name:ui-ncbihistogram-display-area>ol>li>h3;
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:366.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-controls, li.ui-ncbihistogram-controls, div.ui-ncbihistogram-controls
	{mso-style-name:ui-ncbihistogram-controls;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left, li.ui-ncbihistogram-left, div.ui-ncbihistogram-left
	{mso-style-name:ui-ncbihistogram-left;
	margin-right:0in;
	margin-left:2.25pt;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-right, li.ui-ncbihistogram-right, div.ui-ncbihistogram-right
	{mso-style-name:ui-ncbihistogram-right;
	margin-right:2.25pt;
	margin-left:0in;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left-disabled, li.ui-ncbihistogram-left-disabled, div.ui-ncbihistogram-left-disabled
	{mso-style-name:ui-ncbihistogram-left-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-right-disabled, li.ui-ncbihistogram-right-disabled, div.ui-ncbihistogram-right-disabled
	{mso-style-name:ui-ncbihistogram-right-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-text, li.ui-ncbihistogram-text, div.ui-ncbihistogram-text
	{mso-style-name:ui-ncbihistogram-text;
	margin-top:0in;
	margin-right:12.75pt;
	margin-bottom:0in;
	margin-left:12.75pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.8pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-tooltip, li.ui-ncbihistogram-tooltip, div.ui-ncbihistogram-tooltip
	{mso-style-name:ui-ncbihistogram-tooltip;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	display:none;}
p.ncbiactivevalidationmsg, li.ncbiactivevalidationmsg, div.ncbiactivevalidationmsg
	{mso-style-name:ncbiactivevalidation_msg;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ncbiactivevalidationmsgchecking, li.ncbiactivevalidationmsgchecking, div.ncbiactivevalidationmsgchecking
	{mso-style-name:ncbiactivevalidation_msg_checking;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#FF9900;}
p.ncbiactivevalidationmsgvalid, li.ncbiactivevalidationmsgvalid, div.ncbiactivevalidationmsgvalid
	{mso-style-name:ncbiactivevalidation_msg_valid;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:green;}
p.ncbiactivevalidationmsgerror, li.ncbiactivevalidationmsgerror, div.ncbiactivevalidationmsgerror
	{mso-style-name:ncbiactivevalidation_msg_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.ncbiactivevalidationmsginfo, li.ncbiactivevalidationmsginfo, div.ncbiactivevalidationmsginfo
	{mso-style-name:ncbiactivevalidation_msg_info;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:blue;}
p.ncbiactivevalidationelerror, li.ncbiactivevalidationelerror, div.ncbiactivevalidationelerror
	{mso-style-name:ncbiactivevalidation_el_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.social-buttons, li.social-buttons, div.social-buttons
	{mso-style-name:social-buttons;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inlinelist, li.inlinelist, div.inlinelist
	{mso-style-name:inline_list;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inline, li.inline, div.inline
	{mso-style-name:inline;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fig, li.fig, div.fig
	{mso-style-name:fig;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.table, li.table, div.table
	{mso-style-name:table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pmc-wm, li.pmc-wm, div.pmc-wm
	{mso-style-name:pmc-wm;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.attic, li.attic, div.attic
	{mso-style-name:attic;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.basement, li.basement, div.basement
	{mso-style-name:basement;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-breadcrumbs, li.page-breadcrumbs, div.page-breadcrumbs
	{mso-style-name:page-breadcrumbs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.first-line-outdent, li.first-line-outdent, div.first-line-outdent
	{mso-style-name:first-line-outdent;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vatop, li.vatop, div.vatop
	{mso-style-name:va_top;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vamiddle, li.vamiddle, div.vamiddle
	{mso-style-name:va_middle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.qtrhythm, li.qtrhythm, div.qtrhythm
	{mso-style-name:qt_rhythm;
	margin-top:4.15pt;
	margin-right:0in;
	margin-bottom:4.15pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notopmargin, li.notopmargin, div.notopmargin
	{mso-style-name:no_top_margin;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nobottommargin, li.nobottommargin, div.nobottommargin
	{mso-style-name:no_bottom_margin;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tscanvas, li.tscanvas, div.tscanvas
	{mso-style-name:ts_canvas;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tsbar, li.tsbar, div.tsbar
	{mso-style-name:ts_bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#DCF0F4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-reuse, li.fm-reuse, div.fm-reuse
	{mso-style-name:fm-reuse;
	margin-right:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-subtitle, li.fm-subtitle, div.fm-subtitle
	{mso-style-name:fm-subtitle;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:15.0pt;
	font-family:"Times New Roman","serif";}
p.fm-copyright-license, li.fm-copyright-license, div.fm-copyright-license
	{mso-style-name:fm-copyright-license;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-citation-from, li.fm-citation-from, div.fm-citation-from
	{mso-style-name:fm-citation-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-box, li.ft-thumb-box, div.ft-thumb-box
	{mso-style-name:ft-thumb-box;
	margin:8.3pt;
	text-align:center;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-current, li.ft-thumb-current, div.ft-thumb-current
	{mso-style-name:ft-thumb-current;
	margin-right:0in;
	margin-left:0in;
	background:#D0DCE8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tab, li.tab, div.tab
	{mso-style-name:tab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.arrowtab, li.arrowtab, div.arrowtab
	{mso-style-name:arrowtab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.blanktab, li.blanktab, div.blanktab
	{mso-style-name:blanktab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab, li.thistab, div.thistab
	{mso-style-name:thistab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:white;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.doi, li.doi, div.doi
	{mso-style-name:doi;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msg-error, li.msg-error, div.msg-error
	{mso-style-name:msg-error;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.msg-warning, li.msg-warning, div.msg-warning
	{mso-style-name:msg-warning;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:brown;}
p.nihms-highlight, li.nihms-highlight, div.nihms-highlight
	{mso-style-name:nihms-highlight;
	margin-top:0in;
	margin-right:2.4pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:yellow;
	font-size:10.5pt;
	font-family:"Times New Roman","serif";
	color:#990000;}
p.head, li.head, div.head
	{mso-style-name:head;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-head, li.sub-head, div.sub-head
	{mso-style-name:sub-head;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.headless, li.headless, div.headless
	{mso-style-name:headless;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-navigation, li.sub-navigation, div.sub-navigation
	{mso-style-name:sub-navigation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sec, li.sec, div.sec
	{mso-style-name:sec;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content-branding, li.content-branding, div.content-branding
	{mso-style-name:content-branding;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-generic-logo-background, li.banner-generic-logo-background, div.banner-generic-logo-background
	{mso-style-name:banner-generic-logo-background;
	margin-right:0in;
	margin-left:0in;
	background:silver;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.banner-journal-name, li.banner-journal-name, div.banner-journal-name
	{mso-style-name:banner-journal-name;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:20.5pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.3pt;}
p.banner-journal-publisher-over-image, li.banner-journal-publisher-over-image, div.banner-journal-publisher-over-image
	{mso-style-name:banner-journal-publisher-over-image;
	margin-right:7.5pt;
	margin-left:63.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-publisher-name, li.banner-publisher-name, div.banner-publisher-name
	{mso-style-name:banner-publisher-name;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:9.5pt;
	font-family:"Calibri","sans-serif";
	color:#AA1111;
	font-weight:bold;}
p.bl-w-jtitle-over, li.bl-w-jtitle-over, div.bl-w-jtitle-over
	{mso-style-name:bl-w-jtitle-over;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-variant:small-caps;}
p.bl-w-jtitle-over-ph, li.bl-w-jtitle-over-ph, div.bl-w-jtitle-over-ph
	{mso-style-name:bl-w-jtitle-over-ph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-w-jtitle-over-ph-content, li.bl-w-jtitle-over-ph-content, div.bl-w-jtitle-over-ph-content
	{mso-style-name:bl-w-jtitle-over-ph-content;
	margin-top:3.0pt;
	margin-right:6.0pt;
	margin-bottom:3.0pt;
	margin-left:78.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-journal-publisher-over-image-elsevierwt, li.banner-journal-publisher-over-image-elsevierwt, div.banner-journal-publisher-over-image-elsevierwt
	{mso-style-name:banner-journal-publisher-over-image-elsevierwt;
	margin-top:0in;
	margin-right:120.0pt;
	margin-bottom:0in;
	margin-left:15.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.elsevierwt-sponsored-label, li.elsevierwt-sponsored-label, div.elsevierwt-sponsored-label
	{mso-style-name:elsevierwt-sponsored-label;
	margin-right:0in;
	margin-left:-9.0pt;
	line-height:13.5pt;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.9pt;
	font-style:italic;}
p.bl-jtitle-sageopen, li.bl-jtitle-sageopen, div.bl-jtitle-sageopen
	{mso-style-name:bl-jtitle-sageopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055A5;}
p.bl-jtitle-iospressopenlib, li.bl-jtitle-iospressopenlib, div.bl-jtitle-iospressopenlib
	{mso-style-name:bl-jtitle-iospressopenlib;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-apasd, li.bl-jtitle-apasd, div.bl-jtitle-apasd
	{mso-style-name:bl-jtitle-apasd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-springeropen, li.bl-jtitle-springeropen, div.bl-jtitle-springeropen
	{mso-style-name:bl-jtitle-springeropen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#F0F0F0;}
p.bl-jtitle-sfesd, li.bl-jtitle-sfesd, div.bl-jtitle-sfesd
	{mso-style-name:bl-jtitle-sfesd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-acssd, li.bl-jtitle-acssd, div.bl-jtitle-acssd
	{mso-style-name:bl-jtitle-acssd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-esesd, li.bl-jtitle-esesd, div.bl-jtitle-esesd
	{mso-style-name:bl-jtitle-esesd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-srfsd, li.bl-jtitle-srfsd, div.bl-jtitle-srfsd
	{mso-style-name:bl-jtitle-srfsd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-tea, li.bl-jtitle-tea, div.bl-jtitle-tea
	{mso-style-name:bl-jtitle-tea;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#861316;}
p.bl-jtitle-rcpsychsd, li.bl-jtitle-rcpsychsd, div.bl-jtitle-rcpsychsd
	{mso-style-name:bl-jtitle-rcpsychsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#44448A;}
p.bl-jtitle-npgopen, li.bl-jtitle-npgopen, div.bl-jtitle-npgopen
	{mso-style-name:bl-jtitle-npgopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-maneyopen, li.bl-jtitle-maneyopen, div.bl-jtitle-maneyopen
	{mso-style-name:bl-jtitle-maneyopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-bmjgroup, li.bl-jtitle-bmjgroup, div.bl-jtitle-bmjgroup
	{mso-style-name:bl-jtitle-bmjgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#003366;}
p.bl-jtitle-clpt, li.bl-jtitle-clpt, div.bl-jtitle-clpt
	{mso-style-name:bl-jtitle-clpt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-nihpa-wiley, li.bl-jtitle-nihpa-wiley, div.bl-jtitle-nihpa-wiley
	{mso-style-name:bl-jtitle-nihpa-wiley;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-rsmsd, li.bl-jtitle-rsmsd, div.bl-jtitle-rsmsd
	{mso-style-name:bl-jtitle-rsmsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-hogrefesd, li.bl-jtitle-hogrefesd, div.bl-jtitle-hogrefesd
	{mso-style-name:bl-jtitle-hogrefesd;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#025490;}
p.mp-outer, li.mp-outer, div.mp-outer
	{mso-style-name:mp-outer;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mp-outerdiv, li.mp-outerdiv, div.mp-outerdiv
	{mso-style-name:mp-outer>div;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight1, li.toc-highlight1, div.toc-highlight1
	{mso-style-name:toc-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FFFFD0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight2, li.toc-highlight2, div.toc-highlight2
	{mso-style-name:toc-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#ACE4FF;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-hl-inaugural, li.toc-hl-inaugural, div.toc-hl-inaugural
	{mso-style-name:toc-hl-inaugural;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#E64A00;}
p.courtesy-note, li.courtesy-note, div.courtesy-note
	{mso-style-name:courtesy-note;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.footer, li.footer, div.footer
	{mso-style-name:footer;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.suppmat, li.suppmat, div.suppmat
	{mso-style-name:suppmat;
	margin-top:8.3pt;
	margin-right:0in;
	margin-bottom:8.3pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.aligncenter, li.aligncenter, div.aligncenter
	{mso-style-name:align_center;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mul-switcher, li.mul-switcher, div.mul-switcher
	{mso-style-name:mul-switcher;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.strong, li.strong, div.strong
	{mso-style-name:strong;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.red, li.red, div.red
	{mso-style-name:red;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.navigator, li.navigator, div.navigator
	{mso-style-name:navigator;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.summary, li.summary, div.summary
	{mso-style-name:summary;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.head1a, li.head1a, div.head1a
	{mso-style-name:head1a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-header, li.navigator-header, div.navigator-header
	{mso-style-name:navigator-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-footer, li.navigator-footer, div.navigator-footer
	{mso-style-name:navigator-footer;
	margin-top:7.5pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar, li.navigator-bar, div.navigator-bar
	{mso-style-name:navigator-bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-page, li.navigator-page, div.navigator-page
	{mso-style-name:navigator-page;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar-table, li.navigator-bar-table, div.navigator-bar-table
	{mso-style-name:navigator-bar-table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.section-with-images-on-the-same-page, li.section-with-images-on-the-same-page, div.section-with-images-on-the-same-page
	{mso-style-name:section-with-images-on-the-same-page;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.main-archive-list-of-volumes, li.main-archive-list-of-volumes, div.main-archive-list-of-volumes
	{mso-style-name:main-archive-list-of-volumes;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.archive-header, li.archive-header, div.archive-header
	{mso-style-name:archive-header;
	margin-right:0in;
	margin-bottom:7.5pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.journal-block-title, li.journal-block-title, div.journal-block-title
	{mso-style-name:journal-block-title;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.vol-year-cell, li.vol-year-cell, div.vol-year-cell
	{mso-style-name:vol-year-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.issue-block, li.issue-block, div.issue-block
	{mso-style-name:issue-block;
	margin-right:0in;
	margin-left:0in;
	background:#8CACCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-dark-row, li.iss-dark-row, div.iss-dark-row
	{mso-style-name:iss-dark-row;
	margin-right:0in;
	margin-left:0in;
	background:#EFF1F3;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-light-row, li.iss-light-row, div.iss-light-row
	{mso-style-name:iss-light-row;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-cell, li.iss-cell, div.iss-cell
	{mso-style-name:iss-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vol-cell, li.vol-cell, div.vol-cell
	{mso-style-name:vol-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.arc-issue, li.arc-issue, div.arc-issue
	{mso-style-name:arc-issue;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055AA;}
p.large-thumb-canvas, li.large-thumb-canvas, div.large-thumb-canvas
	{mso-style-name:large-thumb-canvas;
	margin:8.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;
	display:none;}
p.co, li.co, div.co
	{mso-style-name:co;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.co-default, li.co-default, div.co-default
	{mso-style-name:co-default;
	margin:8.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.large-thumb-canvas-1, li.large-thumb-canvas-1, div.large-thumb-canvas-1
	{mso-style-name:large-thumb-canvas-1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.co-inner, li.co-inner, div.co-inner
	{mso-style-name:co-inner;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.in-progress, li.in-progress, div.in-progress
	{mso-style-name:in-progress;
	margin:1.5pt;
	background:#444444;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.large-thumb, li.large-thumb, div.large-thumb
	{mso-style-name:large-thumb;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.small-thumb-canvas, li.small-thumb-canvas, div.small-thumb-canvas
	{mso-style-name:small-thumb-canvas;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.small-thumb, li.small-thumb, div.small-thumb
	{mso-style-name:small-thumb;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup-sensitive-area, li.figpopup-sensitive-area, div.figpopup-sensitive-area
	{mso-style-name:figpopup-sensitive-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.print-view, li.print-view, div.print-view
	{mso-style-name:print-view;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.citationexporter-header, li.citationexporter-header, div.citationexporter-header
	{mso-style-name:citationexporter-header;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.citationexporter-footer, li.citationexporter-footer, div.citationexporter-footer
	{mso-style-name:citationexporter-footer;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxpreview, li.mathjaxpreview, div.mathjaxpreview
	{mso-style-name:mathjax_preview;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#888888;}
p.mathjaxerror, li.mathjaxerror, div.mathjaxerror
	{mso-style-name:mathjax_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CC0000;
	font-style:italic;}
p.mathjaxmenu, li.mathjaxmenu, div.mathjaxmenu
	{mso-style-name:mathjax_menu;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;}
p.mathjaxmenuitem, li.mathjaxmenuitem, div.mathjaxmenuitem
	{mso-style-name:mathjax_menuitem;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuarrow, li.mathjaxmenuarrow, div.mathjaxmenuarrow
	{mso-style-name:mathjax_menuarrow;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:#666666;}
p.mathjaxmenucheck, li.mathjaxmenucheck, div.mathjaxmenucheck
	{mso-style-name:mathjax_menucheck;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS","sans-serif";}
p.mathjaxmenulabel, li.mathjaxmenulabel, div.mathjaxmenulabel
	{mso-style-name:mathjax_menulabel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.mathjaxmenurule, li.mathjaxmenurule, div.mathjaxmenurule
	{mso-style-name:mathjax_menurule;
	margin-top:3.0pt;
	margin-right:.75pt;
	margin-bottom:0in;
	margin-left:.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuclose, li.mathjaxmenuclose, div.mathjaxmenuclose
	{mso-style-name:mathjax_menuclose;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.print-log, li.print-log, div.print-log
	{mso-style-name:print-log;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header, li.ui-accordion-header, div.ui-accordion-header
	{mso-style-name:ui-accordion-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons, li.ui-accordion-icons, div.ui-accordion-icons
	{mso-style-name:ui-accordion-icons;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content, li.ui-accordion-content, div.ui-accordion-content
	{mso-style-name:ui-accordion-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text, li.ui-button-text, div.ui-button-text
	{mso-style-name:ui-button-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header, li.ui-datepicker-header, div.ui-datepicker-header
	{mso-style-name:ui-datepicker-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next, li.ui-datepicker-next, div.ui-datepicker-next
	{mso-style-name:ui-datepicker-next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev, li.ui-datepicker-prev, div.ui-datepicker-prev
	{mso-style-name:ui-datepicker-prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title, li.ui-datepicker-title, div.ui-datepicker-title
	{mso-style-name:ui-datepicker-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane, li.ui-datepicker-buttonpane, div.ui-datepicker-buttonpane
	{mso-style-name:ui-datepicker-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group, li.ui-datepicker-group, div.ui-datepicker-group
	{mso-style-name:ui-datepicker-group;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title, li.ui-dialog-title, div.ui-dialog-title
	{mso-style-name:ui-dialog-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane, li.ui-dialog-buttonpane, div.ui-dialog-buttonpane
	{mso-style-name:ui-dialog-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item, li.ui-menu-item, div.ui-menu-item
	{mso-style-name:ui-menu-item;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider, li.ui-menu-divider, div.ui-menu-divider
	{mso-style-name:ui-menu-divider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value, li.ui-progressbar-value, div.ui-progressbar-value
	{mso-style-name:ui-progressbar-value;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay, li.ui-progressbar-overlay, div.ui-progressbar-overlay
	{mso-style-name:ui-progressbar-overlay;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle, li.ui-slider-handle, div.ui-slider-handle
	{mso-style-name:ui-slider-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range, li.ui-slider-range, div.ui-slider-range
	{mso-style-name:ui-slider-range;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav, li.ui-tabs-nav, div.ui-tabs-nav
	{mso-style-name:ui-tabs-nav;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-panel, li.ui-tabs-panel, div.ui-tabs-panel
	{mso-style-name:ui-tabs-panel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide, li.ui-tabs-hide, div.ui-tabs-hide
	{mso-style-name:ui-tabs-hide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar-close, li.ui-dialog-titlebar-close, div.ui-dialog-titlebar-close
	{mso-style-name:ui-dialog-titlebar-close;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content, li.ui-dialog-content, div.ui-dialog-content
	{mso-style-name:ui-dialog-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right, li.ui-ncbiautocomplete-link-pref-right, div.ui-ncbiautocomplete-link-pref-right
	{mso-style-name:ui-ncbiautocomplete-link-pref-right;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary, li.ui-button-icon-primary, div.ui-button-icon-primary
	{mso-style-name:ui-button-icon-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary, li.ui-button-icon-secondary, div.ui-button-icon-secondary
	{mso-style-name:ui-button-icon-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.prev, li.prev, div.prev
	{mso-style-name:prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next, li.next, div.next
	{mso-style-name:next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count, li.ui-ncbigrid-select-row-count, div.ui-ncbigrid-select-row-count
	{mso-style-name:ui-ncbigrid-select-row-count;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenulia, li.ui-ncbibasicmenulia, div.ui-ncbibasicmenulia
	{mso-style-name:ui-ncbibasicmenu>li>a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf, li.ui-ncbimenu-item-leaf, div.ui-ncbimenu-item-leaf
	{mso-style-name:ui-ncbimenu-item-leaf;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop, li.brieflinkpop, div.brieflinkpop
	{mso-style-name:brieflinkpop;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star, li.star, div.star
	{mso-style-name:star;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch, li.jig-ncbisetswitch, div.jig-ncbisetswitch
	{mso-style-name:jig-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-button, li.ui-ncbisetswitch-button, div.ui-ncbisetswitch-button
	{mso-style-name:ui-ncbisetswitch-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options, li.ui-ncbisetswitch-options, div.ui-ncbisetswitch-options
	{mso-style-name:ui-ncbisetswitch-options;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box, li.boxed-text-box, div.boxed-text-box
	{mso-style-name:boxed-text-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from, li.cell-from, div.cell-from
	{mso-style-name:cell-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-citation, li.cell-citation, div.cell-citation
	{mso-style-name:cell-citation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup, li.figpopup, div.figpopup
	{mso-style-name:figpopup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button, li.button, div.button
	{mso-style-name:button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.retraction, li.retraction, div.retraction
	{mso-style-name:retraction;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow, li.mathjaxhoverarrow, div.mathjaxhoverarrow
	{mso-style-name:mathjax_hover_arrow;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody, li.pbody, div.pbody
	{mso-style-name:pbody;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box, li.page-box, div.page-box
	{mso-style-name:page-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide, li.page-box-wide, div.page-box-wide
	{mso-style-name:page-box-wide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth, li.nomaxwidth, div.nomaxwidth
	{mso-style-name:no_max_width;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f, li.f, div.f
	{mso-style-name:f;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l, li.l, div.l
	{mso-style-name:l;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon, li.ui-accordion-header-icon, div.ui-accordion-header-icon
	{mso-style-name:ui-accordion-header-icon;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup, li.ui-selectmenu-optgroup, div.ui-selectmenu-optgroup
	{mso-style-name:ui-selectmenu-optgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor, li.ui-tabs-anchor, div.ui-tabs-anchor
	{mso-style-name:ui-tabs-anchor;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-submit, li.ui-ncbibutton-submit, div.ui-ncbibutton-submit
	{mso-style-name:ui-ncbibutton-submit;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel, li.ui-ncbibutton-cancel, div.ui-ncbibutton-cancel
	{mso-style-name:ui-ncbibutton-cancel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover, li.ltd-hover, div.ltd-hover
	{mso-style-name:ltd-hover;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.warn, li.warn, div.warn
	{mso-style-name:warn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content, li.content, div.content
	{mso-style-name:content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.onelinesource, li.onelinesource, div.onelinesource
	{mso-style-name:one_line_source;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary, li.tertiary, div.tertiary
	{mso-style-name:tertiary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverframe, li.mathjaxhoverframe, div.mathjaxhoverframe
	{mso-style-name:mathjax_hover_frame;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header1, li.ui-accordion-header1, div.ui-accordion-header1
	{mso-style-name:ui-accordion-header1;
	margin-top:1.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons1, li.ui-accordion-icons1, div.ui-accordion-icons1
	{mso-style-name:ui-accordion-icons1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons2, li.ui-accordion-icons2, div.ui-accordion-icons2
	{mso-style-name:ui-accordion-icons2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon1, li.ui-accordion-header-icon1, div.ui-accordion-header-icon1
	{mso-style-name:ui-accordion-header-icon1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content1, li.ui-accordion-content1, div.ui-accordion-content1
	{mso-style-name:ui-accordion-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text1, li.ui-button-text1, div.ui-button-text1
	{mso-style-name:ui-button-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text2, li.ui-button-text2, div.ui-button-text2
	{mso-style-name:ui-button-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text3, li.ui-button-text3, div.ui-button-text3
	{mso-style-name:ui-button-text3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon2, li.ui-icon2, div.ui-icon2
	{mso-style-name:ui-icon2;
	margin-top:0in;
	margin-right:0in;
	margin-left:-6.0pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button1, li.ui-button1, div.ui-button1
	{mso-style-name:ui-button1;
	margin-right:-.05in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header1, li.ui-datepicker-header1, div.ui-datepicker-header1
	{mso-style-name:ui-datepicker-header1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next1, li.ui-datepicker-next1, div.ui-datepicker-next1
	{mso-style-name:ui-datepicker-next1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev1, li.ui-datepicker-prev1, div.ui-datepicker-prev1
	{mso-style-name:ui-datepicker-prev1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title1, li.ui-datepicker-title1, div.ui-datepicker-title1
	{mso-style-name:ui-datepicker-title1;
	margin-top:0in;
	margin-right:27.6pt;
	margin-bottom:0in;
	margin-left:27.6pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane1, li.ui-datepicker-buttonpane1, div.ui-datepicker-buttonpane1
	{mso-style-name:ui-datepicker-buttonpane1;
	margin-top:8.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group1, li.ui-datepicker-group1, div.ui-datepicker-group1
	{mso-style-name:ui-datepicker-group1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group2, li.ui-datepicker-group2, div.ui-datepicker-group2
	{mso-style-name:ui-datepicker-group2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group3, li.ui-datepicker-group3, div.ui-datepicker-group3
	{mso-style-name:ui-datepicker-group3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header2, li.ui-datepicker-header2, div.ui-datepicker-header2
	{mso-style-name:ui-datepicker-header2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header3, li.ui-datepicker-header3, div.ui-datepicker-header3
	{mso-style-name:ui-datepicker-header3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane2, li.ui-datepicker-buttonpane2, div.ui-datepicker-buttonpane2
	{mso-style-name:ui-datepicker-buttonpane2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane3, li.ui-datepicker-buttonpane3, div.ui-datepicker-buttonpane3
	{mso-style-name:ui-datepicker-buttonpane3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header4, li.ui-datepicker-header4, div.ui-datepicker-header4
	{mso-style-name:ui-datepicker-header4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header5, li.ui-datepicker-header5, div.ui-datepicker-header5
	{mso-style-name:ui-datepicker-header5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title1, li.ui-dialog-title1, div.ui-dialog-title1
	{mso-style-name:ui-dialog-title1;
	margin-top:1.2pt;
	margin-right:12.0pt;
	margin-bottom:2.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane1, li.ui-dialog-buttonpane1, div.ui-dialog-buttonpane1
	{mso-style-name:ui-dialog-buttonpane1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-left:0in;
	background:whitesmoke;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item1, li.ui-menu-item1, div.ui-menu-item1
	{mso-style-name:ui-menu-item1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider1, li.ui-menu-divider1, div.ui-menu-divider1
	{mso-style-name:ui-menu-divider1;
	margin-top:3.75pt;
	margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	line-height:0%;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-active1, li.ui-state-active1, div.ui-state-active1
	{mso-style-name:ui-state-active1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus1, li.ui-state-focus1, div.ui-state-focus1
	{mso-style-name:ui-state-focus1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-menu-item2, li.ui-menu-item2, div.ui-menu-item2
	{mso-style-name:ui-menu-item2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon3, li.ui-icon3, div.ui-icon3
	{mso-style-name:ui-icon3;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value1, li.ui-progressbar-value1, div.ui-progressbar-value1
	{mso-style-name:ui-progressbar-value1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay1, li.ui-progressbar-overlay1, div.ui-progressbar-overlay1
	{mso-style-name:ui-progressbar-overlay1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value2, li.ui-progressbar-value2, div.ui-progressbar-value2
	{mso-style-name:ui-progressbar-value2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle1, li.ui-resizable-handle1, div.ui-resizable-handle1
	{mso-style-name:ui-resizable-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-resizable-handle2, li.ui-resizable-handle2, div.ui-resizable-handle2
	{mso-style-name:ui-resizable-handle2;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-menu1, li.ui-menu1, div.ui-menu1
	{mso-style-name:ui-menu1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup1, li.ui-selectmenu-optgroup1, div.ui-selectmenu-optgroup1
	{mso-style-name:ui-selectmenu-optgroup1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-slider-handle1, li.ui-slider-handle1, div.ui-slider-handle1
	{mso-style-name:ui-slider-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range1, li.ui-slider-range1, div.ui-slider-range1
	{mso-style-name:ui-slider-range1;
	margin-right:0in;
	margin-left:0in;
	font-size:8.5pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle2, li.ui-slider-handle2, div.ui-slider-handle2
	{mso-style-name:ui-slider-handle2;
	margin-right:0in;
	margin-left:-.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle3, li.ui-slider-handle3, div.ui-slider-handle3
	{mso-style-name:ui-slider-handle3;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range2, li.ui-slider-range2, div.ui-slider-range2
	{mso-style-name:ui-slider-range2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon5, li.ui-icon5, div.ui-icon5
	{mso-style-name:ui-icon5;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor1, li.ui-tabs-anchor1, div.ui-tabs-anchor1
	{mso-style-name:ui-tabs-anchor1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip1, li.ui-tooltip1, div.ui-tooltip1
	{mso-style-name:ui-tooltip1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget1, li.ui-widget1, div.ui-widget1
	{mso-style-name:ui-widget1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-state-default1, li.ui-state-default1, div.ui-state-default1
	{mso-style-name:ui-state-default1;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-default2, li.ui-state-default2, div.ui-state-default2
	{mso-style-name:ui-state-default2;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus2, li.ui-state-focus2, div.ui-state-focus2
	{mso-style-name:ui-state-focus2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover1, li.ui-state-hover1, div.ui-state-hover1
	{mso-style-name:ui-state-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus3, li.ui-state-focus3, div.ui-state-focus3
	{mso-style-name:ui-state-focus3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover2, li.ui-state-hover2, div.ui-state-hover2
	{mso-style-name:ui-state-hover2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active2, li.ui-state-active2, div.ui-state-active2
	{mso-style-name:ui-state-active2;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active3, li.ui-state-active3, div.ui-state-active3
	{mso-style-name:ui-state-active3;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight1, li.ui-state-highlight1, div.ui-state-highlight1
	{mso-style-name:ui-state-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-highlight2, li.ui-state-highlight2, div.ui-state-highlight2
	{mso-style-name:ui-state-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error1, li.ui-state-error1, div.ui-state-error1
	{mso-style-name:ui-state-error1;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error2, li.ui-state-error2, div.ui-state-error2
	{mso-style-name:ui-state-error2;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text1, li.ui-state-error-text1, div.ui-state-error-text1
	{mso-style-name:ui-state-error-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text2, li.ui-state-error-text2, div.ui-state-error-text2
	{mso-style-name:ui-state-error-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary1, li.ui-priority-primary1, div.ui-priority-primary1
	{mso-style-name:ui-priority-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-primary2, li.ui-priority-primary2, div.ui-priority-primary2
	{mso-style-name:ui-priority-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary1, li.ui-priority-secondary1, div.ui-priority-secondary1
	{mso-style-name:ui-priority-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-priority-secondary2, li.ui-priority-secondary2, div.ui-priority-secondary2
	{mso-style-name:ui-priority-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled1, li.ui-state-disabled1, div.ui-state-disabled1
	{mso-style-name:ui-state-disabled1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled2, li.ui-state-disabled2, div.ui-state-disabled2
	{mso-style-name:ui-state-disabled2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon6, li.ui-icon6, div.ui-icon6
	{mso-style-name:ui-icon6;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon7, li.ui-icon7, div.ui-icon7
	{mso-style-name:ui-icon7;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon8, li.ui-icon8, div.ui-icon8
	{mso-style-name:ui-icon8;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon9, li.ui-icon9, div.ui-icon9
	{mso-style-name:ui-icon9;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon10, li.ui-icon10, div.ui-icon10
	{mso-style-name:ui-icon10;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon11, li.ui-icon11, div.ui-icon11
	{mso-style-name:ui-icon11;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon12, li.ui-icon12, div.ui-icon12
	{mso-style-name:ui-icon12;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon13, li.ui-icon13, div.ui-icon13
	{mso-style-name:ui-icon13;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon14, li.ui-icon14, div.ui-icon14
	{mso-style-name:ui-icon14;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav1, li.ui-tabs-nav1, div.ui-tabs-nav1
	{mso-style-name:ui-tabs-nav1;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary1, li.tertiary1, div.tertiary1
	{mso-style-name:tertiary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#666666;}
p.tertiary2, li.tertiary2, div.tertiary2
	{mso-style-name:tertiary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#985735;}
p.ui-tabs-panel1, li.ui-tabs-panel1, div.ui-tabs-panel1
	{mso-style-name:ui-tabs-panel1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide1, li.ui-tabs-hide1, div.ui-tabs-hide1
	{mso-style-name:ui-tabs-hide1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-dialog-titlebar1, li.ui-dialog-titlebar1, div.ui-dialog-titlebar1
	{mso-style-name:ui-dialog-titlebar1;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-dialog-titlebar-close1, li.ui-dialog-titlebar-close1, div.ui-dialog-titlebar-close1
	{mso-style-name:ui-dialog-titlebar-close1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content1, li.ui-dialog-content1, div.ui-dialog-content1
	{mso-style-name:ui-dialog-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se1, li.ui-resizable-se1, div.ui-resizable-se1
	{mso-style-name:ui-resizable-se1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon15, li.ui-icon15, div.ui-icon15
	{mso-style-name:ui-icon15;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-hover3, li.ui-state-hover3, div.ui-state-hover3
	{mso-style-name:ui-state-hover3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-ncbibutton-submit1, li.ui-ncbibutton-submit1, div.ui-ncbibutton-submit1
	{mso-style-name:ui-ncbibutton-submit1;
	margin-right:6.55pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel1, li.ui-ncbibutton-cancel1, div.ui-ncbibutton-cancel1
	{mso-style-name:ui-ncbibutton-cancel1;
	margin-right:0in;
	margin-left:0in;
	line-height:22.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#2F4A8B;}
p.ui-button-text4, li.ui-button-text4, div.ui-button-text4
	{mso-style-name:ui-button-text4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right1, li.ui-ncbiautocomplete-link-pref-right1, div.ui-ncbiautocomplete-link-pref-right1
	{mso-style-name:ui-ncbiautocomplete-link-pref-right1;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text5, li.ui-button-text5, div.ui-button-text5
	{mso-style-name:ui-button-text5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text6, li.ui-button-text6, div.ui-button-text6
	{mso-style-name:ui-button-text6;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text7, li.ui-button-text7, div.ui-button-text7
	{mso-style-name:ui-button-text7;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text8, li.ui-button-text8, div.ui-button-text8
	{mso-style-name:ui-button-text8;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text9, li.ui-button-text9, div.ui-button-text9
	{mso-style-name:ui-button-text9;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text10, li.ui-button-text10, div.ui-button-text10
	{mso-style-name:ui-button-text10;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon16, li.ui-icon16, div.ui-icon16
	{mso-style-name:ui-icon16;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon17, li.ui-icon17, div.ui-icon17
	{mso-style-name:ui-icon17;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon18, li.ui-icon18, div.ui-icon18
	{mso-style-name:ui-icon18;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon19, li.ui-icon19, div.ui-icon19
	{mso-style-name:ui-icon19;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon20, li.ui-icon20, div.ui-icon20
	{mso-style-name:ui-icon20;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon21, li.ui-icon21, div.ui-icon21
	{mso-style-name:ui-icon21;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary1, li.ui-button-icon-primary1, div.ui-button-icon-primary1
	{mso-style-name:ui-button-icon-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary2, li.ui-button-icon-primary2, div.ui-button-icon-primary2
	{mso-style-name:ui-button-icon-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary3, li.ui-button-icon-primary3, div.ui-button-icon-primary3
	{mso-style-name:ui-button-icon-primary3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary1, li.ui-button-icon-secondary1, div.ui-button-icon-secondary1
	{mso-style-name:ui-button-icon-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary2, li.ui-button-icon-secondary2, div.ui-button-icon-secondary2
	{mso-style-name:ui-button-icon-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol1, li.ui-ncbigrid-paged-pagecontrol1, div.ui-ncbigrid-paged-pagecontrol1
	{mso-style-name:ui-ncbigrid-paged-pagecontrol1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.prev1, li.prev1, div.prev1
	{mso-style-name:prev1;
	margin-right:.1in;
	margin-left:2.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next1, li.next1, div.next1
	{mso-style-name:next1;
	margin-right:2.4pt;
	margin-left:.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count1, li.ui-ncbigrid-select-row-count1, div.ui-ncbigrid-select-row-count1
	{mso-style-name:ui-ncbigrid-select-row-count1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-ncbigrid-outer-div1, li.ui-ncbigrid-outer-div1, div.ui-ncbigrid-outer-div1
	{mso-style-name:ui-ncbigrid-outer-div1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf1, li.ui-ncbimenu-item-leaf1, div.ui-ncbimenu-item-leaf1
	{mso-style-name:ui-ncbimenu-item-leaf1;
	margin-top:0in;
	margin-right:9.0pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop1, li.brieflinkpop1, div.brieflinkpop1
	{mso-style-name:brieflinkpop1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star1, li.star1, div.star1
	{mso-style-name:star1;
	margin-right:7.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch1, li.jig-ncbisetswitch1, div.jig-ncbisetswitch1
	{mso-style-name:jig-ncbisetswitch1;
	margin-right:0in;
	margin-left:0in;
	line-height:14.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#333333;}
p.ui-ncbisetswitch-button1, li.ui-ncbisetswitch-button1, div.ui-ncbisetswitch-button1
	{mso-style-name:ui-ncbisetswitch-button1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon24, li.ui-icon24, div.ui-icon24
	{mso-style-name:ui-icon24;
	margin:5.55pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover1, li.ltd-hover1, div.ltd-hover1
	{mso-style-name:ltd-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#E8E8E8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon25, li.ui-icon25, div.ui-icon25
	{mso-style-name:ui-icon25;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options1, li.ui-ncbisetswitch-options1, div.ui-ncbisetswitch-options1
	{mso-style-name:ui-ncbisetswitch-options1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody1, li.pbody1, div.pbody1
	{mso-style-name:pbody1;
	margin-top:0in;
	margin-right:16.6pt;
	margin-bottom:0in;
	margin-left:16.6pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box1, li.page-box1, div.page-box1
	{mso-style-name:page-box1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide1, li.page-box-wide1, div.page-box-wide1
	{mso-style-name:page-box-wide1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth1, li.nomaxwidth1, div.nomaxwidth1
	{mso-style-name:no_max_width1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content1, li.content1, div.content1
	{mso-style-name:content1;
	margin:16.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box1, li.boxed-text-box1, div.boxed-text-box1
	{mso-style-name:boxed-text-box1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f1, li.f1, div.f1
	{mso-style-name:f1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l1, li.l1, div.l1
	{mso-style-name:l1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from1, li.cell-from1, div.cell-from1
	{mso-style-name:cell-from1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.cell-citation1, li.cell-citation1, div.cell-citation1
	{mso-style-name:cell-citation1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup1, li.figpopup1, div.figpopup1
	{mso-style-name:figpopup1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button1, li.button1, div.button1
	{mso-style-name:button1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#336699;}
p.retraction1, li.retraction1, div.retraction1
	{mso-style-name:retraction1;
	margin-right:0in;
	margin-left:0in;
	background:red;
	font-size:12.0pt;
	font-family:"Helvetica","sans-serif";
	color:#F0F0F0;}
p.warn1, li.warn1, div.warn1
	{mso-style-name:warn1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice1, li.notice1, div.notice1
	{mso-style-name:notice1;
	margin-right:0in;
	margin-left:0in;
	font-size:16.5pt;
	font-family:"Times New Roman","serif";}
p.arrowtab1, li.arrowtab1, div.arrowtab1
	{mso-style-name:arrowtab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab1, li.thistab1, div.thistab1
	{mso-style-name:thistab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:9.5pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.onelinesource1, li.onelinesource1, div.onelinesource1
	{mso-style-name:one_line_source1;
	margin-right:0in;
	margin-left:0in;
	background:#E0E0E0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow1, li.mathjaxhoverarrow1, div.mathjaxhoverarrow1
	{mso-style-name:mathjax_hover_arrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:7.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.mathjaxmenuarrow1, li.mathjaxmenuarrow1, div.mathjaxmenuarrow1
	{mso-style-name:mathjax_menuarrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:white;}
p.p, li.p, div.p
	{mso-style-name:p;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msochpdefault, li.msochpdefault, div.msochpdefault
	{mso-style-name:msochpdefault;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";}
p.msopapdefault, li.msopapdefault, div.msopapdefault
	{mso-style-name:msopapdefault;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.other-issues
	{mso-style-name:other-issues;}
span.underline
	{mso-style-name:underline;}
span.double-underline
	{mso-style-name:double-underline;}
span.bold-double-underline
	{mso-style-name:bold-double-underline;}
span.ui-icon1
	{mso-style-name:ui-icon1;}
span.ui-selectmenu-text
	{mso-style-name:ui-selectmenu-text;}
span.pagelink
	{mso-style-name:page_link;}
span.ui-icon-plus-minus-big
	{mso-style-name:ui-icon-plus-minus-big;}
span.ui-icon-plus-minus-big-open
	{mso-style-name:ui-icon-plus-minus-big-open;}
span.collapsabletbodyicon
	{mso-style-name:collapsabletbodyicon;}
span.ui-icon4
	{mso-style-name:ui-icon4;}
span.ui-selectmenu-text1
	{mso-style-name:ui-selectmenu-text1;}
span.pagelink1
	{mso-style-name:page_link1;
	color:#CCCCCC;}
span.collapsabletbodyicon1
	{mso-style-name:collapsabletbodyicon1;}
span.ui-icon-plus-minus-big1
	{mso-style-name:ui-icon-plus-minus-big1;}
span.ui-icon-plus-minus-big-open1
	{mso-style-name:ui-icon-plus-minus-big-open1;}
span.ui-icon-plus-minus-big2
	{mso-style-name:ui-icon-plus-minus-big2;}
span.ui-icon-plus-minus-big-open2
	{mso-style-name:ui-icon-plus-minus-big-open2;}
span.ui-icon22
	{mso-style-name:ui-icon22;}
span.ui-icon23
	{mso-style-name:ui-icon23;}
span.cit
	{mso-style-name:cit;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;}
span.doi1
	{mso-style-name:doi1;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;}
span.before-email-separator
	{mso-style-name:before-email-separator;}
span.email-label
	{mso-style-name:email-label;}
span.kwd-text
	{mso-style-name:kwd-text;}
span.figpopup-sensitive-area1
	{mso-style-name:figpopup-sensitive-area1;
	text-decoration:none none;}
span.citation
	{mso-style-name:citation;}
span.ref-journal
	{mso-style-name:ref-journal;}
span.ref-vol
	{mso-style-name:ref-vol;}
span.nowrap
	{mso-style-name:nowrap;}
.MsoChpDefault
	{font-size:10.0pt;
	font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=313 height=71 src="PMC2538768%20table%202_files/image001.png"><span
style='font-size:12.0pt;font-family:"Times New Roman","serif"'><img width=500
height=75 src="PMC2538768%20table%202_files/image002.gif"
alt="Logo of brjcancer"></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Br
J Cancer. 2008 Sep 16; 99(6): 923�929. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Published
online 2008 Aug 26. doi:&nbsp; <a
href="http://dx.doi.org/10.1038%2Fsj.bjc.6604629" target="pmc_ext">10.1038/sj.bjc.6604629</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMCID:
PMC2538768</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif"'>Comparison of <i>EGFR</i>
and <i>K-RAS</i> gene status between primary tumours and corresponding
metastases in NSCLC</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kalikaki%20A%5Bauth%5D">A
Kalikaki</a>,<sup>1</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Koutsopoulos%20A%5Bauth%5D">A
Koutsopoulos</a>,<sup>2</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Trypaki%20M%5Bauth%5D">M Trypaki</a>,<sup>1</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Souglakos%20J%5Bauth%5D">J
Souglakos</a>,<sup>1,3</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Stathopoulos%20E%5Bauth%5D">E
Stathopoulos</a>,<sup>2</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Georgoulias%20V%5Bauth%5D">V
Georgoulias</a>,<sup>1,3</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Mavroudis%20D%5Bauth%5D">D
Mavroudis</a>,<sup>1,3</sup> and <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Voutsina%20A%5Bauth%5D">A Voutsina</a><sup>1,*</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>1</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Laboratory of Tumor Cell Biology,
School of Medicine, University of Crete, Heraklion, Crete, Greece</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>2</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Pathology, University
General Hospital of Heraklion, Heraklion, Crete, Greece</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>3</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Medical Oncology, University
General Hospital of Heraklion, Heraklion, Crete, Greece</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>*</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Author for correspondence: Email: <a
href="mailto:dev@null">rg.cou.dem@cesgroeg</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/">Author information &#9658;</a>
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/">Article notes &#9658;</a>
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/">Copyright and
License information &#9658;</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Received 2008 May 2; Revised 2008 Aug 1; Accepted 2008 Aug 1.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>
2008, Cancer Research UK</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
article has been <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/citedby/">cited by</a>
other articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>Abstract</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In non-small-cell lung cancer
(NSCLC), epidermal growth factor receptor (<i>EGFR</i>) and <i>K-RAS</i>
mutations of the primary tumour are associated with responsiveness and resistance
to tyrosine kinase inhibitors (TKIs), respectively. However, the <i>EGFR</i>
and <i>K-RAS</i> mutation status in metastases is not well studied. We compared
the mutation status of these genes between the primary tumours and the
corresponding metastases of 25 patients. Epidermal growth factor receptor and <i>K-RAS</i>
mutation status was different between primary tumours and corresponding
metastases in 7 (28%) and 6 (24%) of the 25 patients, respectively. Among the
25 primary tumours, three �hotspot' and two non-classical <i>EGFR</i> mutations
were found; none of the corresponding metastases had the same mutation pattern.
Among the five (20%) <i>K-RAS</i> mutations detected in the primary tumours,
two were maintained in the corresponding metastasis. Epidermal growth factor
receptor and <i>K-RAS</i> mutations were detected in the metastatic tumours of
three (12%) and five (20%) patients, respectively. The expressions of EGFR and
phosphorylated EGFR showed 10 and 50% discordance, in that order. We conclude
that there is substantial discordance in <i>EGFR</i> and <i>K-RAS</i>
mutational status between the primary tumours and corresponding metastases in
patients with NSCLC and this might have therapeutic implications when treatment
with TKIs is considered.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Keywords:
</span></b><i><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>EGFR</span></i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>, <i>K-RAS</i>,
mutations, primary tumour, metastasis, NSCLC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Lung cancer is the most frequent
solid tumour and represents the leading cause of cancer death throughout the
developed world. Almost 70% of patients with non-small-cell lung carcinoma
(NSCLC) present with locally advanced or metastatic disease at the time of
diagnosis. Non-small-cell lung carcinoma is characterised by the accumulation
of multiple genetic alterations (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib30">Marsit <i>et
al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib49">Yokota and
Kohno, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib15">Garnis <i>et
al</i>, 2006</a>). Mutations within the tyrosine kinase domain of epidermal
growth factor receptor (<i>EGFR</i>) account for increased sensitivity to
tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) and they are
associated with prolonged overall survival (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib29">Lynch <i>et
al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib32">Paez <i>et al</i>,
2004</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib36">Perez-Soler
<i>et al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib7">Chou <i>et al</i>,
2005</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib41">Taron
<i>et al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib19">Hirsch, 2006</a>).
However, the point mutation T790M and an insertion mutation in exon 20 were
associated with resistance to TKIs (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib16">Gazdar and
Minna, 2005</a>). Furthermore, recent studies have shown that the expression of
EGFR as assessed by gene copy number, mRNA and protein levels could be used to
predict responsiveness to therapy with TKIs (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib21">Hirsch <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib41">Taron <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib9">Dacic <i>et al</i>,
2006</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib11">Dziadziuszko
<i>et al</i>, 2006</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib12">Endo <i>et al</i>,
2006</a>). In addition, several clinicopathological characteristics, such as
adenocarcinoma histology, non-smoking history, female gender and Asian origin,
are also associated with a higher probability of response to TKIs, whereas the
presence of <i>K-RAS</i> mutations seems to be correlated with primary
resistance to these agents (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib42">Tokumo <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib45">Tsao <i>et al</i>,
2005</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib47">van
Zandwijk <i>et al</i>, 2007</a>). Thus, an emerging issue concerning
EGFR-targeted therapy is to identify the best method for selecting patients who
are more likely to benefit from EGFR inhibition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Advanced NSCLC metastasises
systemically to diverse sites, such as the brain, bone, adrenal glands and
liver. The classical model for the metastatic process suggests that most cells
of a given primary tumour have low metastatic potential and only a few cells
acquire enough somatic mutations to become metastatic (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib2">Bernards and
Weinberg, 2002</a>). An alternative model proposes that the metastatic
potential is encoded in the mass of a given primary tumour that has progressed
to a pre-metastatic state, after which metastases may randomly occur without
any further gene expression changes (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib46">van �t Veer <i>et
al</i>, 2002</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib23">Hynes, 2003</a>;
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib48">Van't Veer
and Weigelt, 2003</a>). Taking into account these two models, a critical issue
for the treatment of metastatic NSCLC is the question of genetic variability
and differences between the primary tumour and the corresponding metastases. In
the majority of studies, <i>EGFR</i> and <i>K-RAS</i> status was determined on
the primary tumours and there are very few data concerning those of corresponding
metastases (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib24">Italiano
<i>et al</i>, 2006</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib31">Matsumoto <i>et
al</i>, 2006</a>). Therefore, it is unclear whether the same <i>EGFR</i> and <i>K-RAS</i>
mutations are also present in the metastatic lesions or whether clones with
different mutations are responsible for the generation of metastases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In this study, the mutation
status of <i>EGFR</i> and <i>K-RAS</i> as well as the EGFR and p-EGFR
expressions on the primary tumours and the corresponding metastatic lesions
were evaluated in 25 patients with advanced NSCLC. The objective of this study
was to investigate the prevalence of <i>EGFR</i> and <i>K-RAS</i> mutations in
metastases and to examine whether these mutations and the EGFR expression
patterns are discordant between the primary tumours and the corresponding
metastases. Secondary objectives were to explore whether the EGFR expression
pattern correlated to <i>EGFR</i> and/or <i>K-RAS</i> mutations in both the
primary tumours and corresponding metastases.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>Patients and methods</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Patients </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Patients, aged &gt;18 years old,
with histologically confirmed NSCLC who underwent biopsy or surgical excision
of the primary tumour and the corresponding metastases were included in this
retrospective analysis. Histological type was determined according to the World
Health Organization criteria, and the stage of the disease corresponds to that
of the time of primary diagnosis. Smoking history was obtained during the
patient's first evaluation. All patients gave their informed consent for using
their tumour sample for molecular and pathologic analysis. The study has been
approved by the Ethics and Scientific Committees of our institution.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>DNA extraction
and mutation analysis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>All tumour samples were
formalin-fixed paraffin-embedded tissues. Sections of a paraffin block
corresponding to one representative area of the tumour were stained with
haematoxylin/eosin, and the presence of tumour tissue was verified by an
experienced pathologist. Subsequently, tissue samples from at least three
serial sections were microdissected (piezo power Eppendorf Microdissector;
Eppendorf, Germany) to ensure that specimens contained at least 80% tumour
cells; sections of 5&#8201;<i>&#956;</i>m thickness were also collected from
adjacent normal tissue when available, extracted with xylene and ethanol to
remove paraffin and placed in 1% SDS/proteinase K (10&#8201;mg&#8201;ml<sup>&#8722;1</sup>)
at 56�C overnight. DNA was extracted using the MasterPure Complete DNA/RNA
Purification kit (Epicentre Biotechnologies, Madison, WI, USA) according to the
manufacturer's instructions. Exons 18, 19, 20 and 21 of the EGFR and exon 1 of
K-RAS were sequentially amplified by two rounds of polymerase chain reaction
(PCR) and subjected to direct sequencing. The PCR primers for <i>EGFR</i>
amplification were as follows: 155273L23: 5&#8242;-TCCCAAACACTCAGTGAAACAAA-3&#8242;;
155348L22: 5&#8242;-TGGTCTCACAGGACCACTGATT-3&#8242;; 154838U22: 5&#8242;-TCAGAGCCTGTGTTTCTACCAA-3&#8242;;
154899U20: 5&#8242;-TCCAAATGAGCTGGCAAGTG-3&#8242;; 55634U24: 5&#8242;-AAATAATCAGTGTGATTCGTGGAG-3&#8242;;
156027L20: 5&#8242;-TGTGGAGATGAGCAGGGTCT-3&#8242;; 156107L22: 5&#8242;-GAGGCCAGTGCTGTCTCTAAGG-3&#8242;;
155750U20: 5&#8242;-GTGCATCGCTGGTAACATCC-3&#8242;; 173160L22: 5&#8242;-CAGCTCTGGCTCACACTACCAG-3&#8242;;
173076L19: 5&#8242;-CATCCTCCCCTGCATGTGT-3&#8242;; 172656U22: 5&#8242;-GCAGCGGGTTACATCTTCTTTC-3&#8242;;
and 172747U19: 5&#8242;-GCT CAGAGCCTGGCATGAA-3&#8242;. The PCR primers for <i>K-RAS</i>
amplification were as follows: RASU1: 5&#8242;-AGGCCTGCTGAAAATGACTGAATA-3&#8242;;
RASL1: 5&#8242;-CTGTATCAAAGAATGGTCCTGCAC-3&#8242;; RASU2: 5&#8242;-AAAATGACTGAATATAAACTTGTGG-3&#8242;;
RASL2: 5&#8242;-CTCTATTGTTGGATCATATTCGTC-3&#8242;. The first PCR was carried
out in a total volume of 10&#8201;<i>&#956;</i>l contained 1/10 of the
extracted genomic DNA using 1&#8201;U of Platinum Taq DNA polymerase (Invitrogen
Corporation, Carlsbad, CA, USA). The initial denaturing step was at 94�C for 15&#8201;min,
followed by 35 cycles of denaturing step at 94�C for 20&#8201;s, annealing step
at 60�C for 30&#8201;s and extension step at 72�C for 1&#8201;min, ending with
a final extension step at 72�C for 7&#8201;min. Nested PCR was carried out in a
total volume of 20&#8201;<i>&#956;</i>l and the conditions were identical to
the first PCR. The PCR products are directly sequenced by dye terminator
sequencing (ABI BigDye Terminator kit, v3.1, Applied Biosystems, Foster City,
CA, USA), purified by ethanol precipitation and separated by capillary
electrophoresis on an ABI 3100 Avant genetic analyzer (Applied Biosystems).
Sequence analysis was carried out by Seqscape software (Applied Biosystems) and
manually by two reviewers (AK and AV). All sequence variations were confirmed
by sequencing in both directions and by an independent PCR amplification when
sufficient material was available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The sensitivity of our
methodology was evaluated by determining the minimum frequency of <i>EGFR</i>
and <i>K-RAS</i> mutations required for detection in our system. This was
accomplished by performing mixing experiments using cell lines with and without
<i>EGFR</i> (H2073-wt-<i>EGFR</i> and HCC827-Del19-<i>EGFR</i>) or <i>K-RAS</i>
(H2073-wt-<i>K-RAS</i> and A549-G12D-<i>K-RAS</i>) mutations. These experiments
demonstrated that the Del19 and <i>K-RAS</i> mutations could be detected when
present in 10 and 20% of the cells in the sample, respectively (data not
shown).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Immunohistochemistry
for EGFR </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The paraffin-embedded tissues
were cut at 4&#8201;<i>&#956;</i>m thickness and were deposited on
SuperFrost/Plus Slides (O.Kindler GmbH, Freiburg, Germany). After
deparaffinisation, the slides for EGFR were treated with proteinase K (Code
S3020, DakoCytomation, Glostrup, Denmark) for 5&#8201;min at room temperature,
and those for p-EGFR were treated with EDTA at pH 8 in a microwave oven three
times for 5&#8201;min at 500&#8201;W for antigen retrieval. The primary
anti-EGFR antibody (mouse monoclonal, clone H11, code M3563, DakoCytomation)
was used at a dilution of 1&#8201;:&#8201;50 (v/v) and incubated for 1&#8201;h
at room temperature. The primary anti-phospho-EGFR antibody (rabbit monoclonal,
pY1173-EGFR, code no. 4407, Cell Signalling, Danvers, MA, USA) was used at a
dilution of 1&#8201;:&#8201;200 (v/v) and incubated overnight at 4�C. For the
detection of antigen-antibody reaction, the UltraVision detection system AP
Polymer kit (Cat no. TL-125-AL, Lab Vision, Fremont, CA, USA) was used
according to the manufacturer's instructions. Fast red was used as chromogen
for 20&#8201;min; the sections were counterstained with Mayer's haematoxylin
for 3&#8201;min, subsequently rinsed in ammonium and finally mounted with
glycergel. A positive (an NSCLC tumour specimen with known positivity) and a
negative (omission of primary antibody) control were used. The stained sections
were independently evaluated by two pathologists (AK and ES). Immunoreactions
of EGFR were graded as 3+ when strong complete membrane staining was observed
in more than 10% of the tumour cells, as 2+ when more than 10% of the tumour
cells showed weak-to-moderate complete membrane staining, as 1+ when partially,
faint membrane stain was detected in more than 10% of the tumour cells and as 0
when no staining at all or membrane staining in less than 10% of the tumour
cells was observed. In this study, we arbitrarily classified EGFR expression
status in two subsets; the 2+ or 3+ signals were considered as EGFR
overexpression and the 0 or 1+ signals as non-expression (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib25">Koutsopoulos <i>et
al</i>, 2007</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>A paraffin block from the HCC827
lung epithelial adenocarcinoma cell line and commercially available positive
controls (SignalSlide Phospho-EGF Receptor (Tyr1173) IHC Controls, code no.
8102, Cell Signalling) was used to validate the antibody for p-EGFR. pY1173-EGFR
immunostaining was mainly membranous and was graded as 0 (&lt;5% positive
cells), 1+ (5�19% positive cells), 2+ (20�50% positive cells) and 3+ (&gt;50%
positive cells) (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib8">Cortas <i>et
al</i>, 2007</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Statistical
analysis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>McNemar test was used to compare
the <i>EGFR</i> and <i>K-RAS</i> status between primary tumours and related
metastatic sites. Differences were considered statistically significant when
the <i>P</i>-value was &lt;0.05. All statistical tests were two-sided.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>Results</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Patient
characteristics </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Twenty-two (88%) patients were
men and 22 (88%) were active or former smokers and their median age was 55
years (range, 41�70). Eighteen (72%) patients had adenocarcinomas (ADC) and 21
(84%) patients had stage III or IV disease. Among the 50 samples analysed (25
primary tumours and 25 metastases), 26 (52%) samples were surgical and 24 (48%)
biopsies. The primary tumour tissue was the lung (<i>n</i>=25 patients); and
the origin of the metastatic sample was lung (<i>n</i>=9 patients), thoracic
wall (<i>n</i>=5 patients), adrenal gland (<i>n</i>=4 patients), brain (<i>n</i>=3
patients), bone (<i>n</i>=2 patients), liver (<i>n</i>=1 patient) and skin (<i>n</i>=1
patient). Metastases were metachronous in all cases; the median time elapsed
between resection of the primary tumour and the corresponding metastatic site
was 30 months (range, 4�143). The patients' clinicopathologic characteristics
are presented in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl1/"
target=true>Table 1</a>. <span style='background:yellow'>Nine (36%) patients
were treated with gefitinib in the context of an Expanded Access Program (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>).</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl1/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140
src="PMC2538768%20table%202_files/image003.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl1/"
target=table>Table 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Patient's
clinicopathological characteristics</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140
src="PMC2538768%20table%202_files/image004.png" alt="Table 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=table>Table 2</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
background:yellow'><i>EGFR</i> and <i>K-RAS</i>
status in paired primary and metastatic tumours</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>EGFR</span></i></b><b><span
lang=EN style='font-size:13.5pt;font-family:"Times New Roman","serif"'> mutation
status of the primary tumours and the corresponding metastasis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>The <i>EGFR</i>
mutation status of the primary tumours and the corresponding metastases is
presented in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>.</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Epidermal growth factor receptor mutations were
detected in the primary tumours of five (20%) patients; of these, three of them
were the well-characterised �hotspot' mutations in exon 19 (Del746-750 and
E746V; case nos. 20, 23 and 18) and the remaining two were novel point
mutations in exons 18 and 21 (L692P and G857E; case nos. 17 and 19),
respectively.</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> The corresponding metastases of the Del746-750 (case no. 23),
E746V (no. 18), L692P (no. 17) and G857E (no. 19) mutant primary tumours were wild
type with respect to <i>EGFR</i> mutation status.</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Epidermal growth factor
receptor mutations were detected in the metastatic tumours of three (12%)
patients (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> The metastasis of one of these patients showed the
same <i>EGFR</i> mutation (Del19) as the primary tumour as well as an
additional one, the T790M in exon 20 (no. 20); conversely, the other two
patients carried two novel mutations in exon 18 (L692P and V717A; no. 12) and
the T847A (no. 13) in exon 21, which could not be detected in the patients'
primary tumour samples.</span><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'> We have confirmed that the non-classical mutations
detected in our series are not single nucleotide polymorphisms by mutation
analysis of matched normal tissue or blood (data not shown).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Consequently, the <i>EGFR</i>
gene status could be classified as: (i) <i>EGFR</i> wild type in both primary
tumour and metastasis (<i>n</i>=18 patients; 72%), and (ii) <i>EGFR</i>
mutations detected only in the primary tumour (<i>n</i>=4 patients; 16%) or the
metastases (<i>n</i>=2 patients; 8%) or both (<i>n</i>=1 patient; 4%).
Therefore, <i>EGFR</i> mutation status showed a discordance of 28% (7 of 25
patients) (McNemar test, <i>P</i>=0.688) between the primary tumour and
corresponding metastasis (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl3/"
target=true>Table 3</a>).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl3/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=119
src="PMC2538768%20table%202_files/image005.png" alt="Table 3"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl3/"
target=table>Table 3</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Combined
analysis of <i>EGFR</i> and <i>K-RAS</i> mutation status</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>EGFR and p-EGFR expression
by IHC in the primary tumour and the corresponding metastases </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>�n 19 patients
sufficient tumour tissue was available for immunohistochemical analysis of EGFR
(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Tables 2</a> and <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl4/"
target=true>&#8203;4</a>).</span> <span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>The incidence of EGFR overexpression (grade 2+, 3+)
was 26.5% in both primary and metastatic tumours.</span> Concordance between
the primary tumour and the corresponding metastases was observed in 17 (89.5)
patients (Cohen's Kappa=0.729, <i>P</i>=0.001) and among them EGFR was
overexpressed in four (21.1%). Discordance was observed in two (10.5%) patients
(nos. 14 and 15) (McNemar test, <i>P</i>=1). Evaluable paired tissue specimens
for p-EGFR analysis by IHC were available in 16 patients. Three out of 16
(18.8%) primary and seven out of 16 (43.8%) metastatic tumours expressed
phosphorylated EGFR (pY1173-EGFR-positive). Discordance between the primary and
metastatic tumours was observed in eight (50%) patients (McNemar test, <i>P</i>=1)
(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Tables 2</a> and <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl4/"
target=true>&#8203;<span style='text-decoration:none'>and4).</span>4</a>).
There was no correlation between the expression of EGFR and pY1173-EGFR. In
order to confirm our findings, we repeated the immunohistochemistry from serial
sections in all tumour specimens that exhibited EGFR-negative and
p-EGFR-positive staining and the obtained results were identical. Epidermal
growth factor receptor gene copy number was also investigated by fluorescence <i>in
situ</i> hybridisation in eight patients (nos. 2, 5, 7, 9, 10, 13, 19 and 24)
for whom paired tissue specimens were available; amplification of <i>EGFR</i>
gene was not detected in any of these tumour specimens.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl4/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=115
src="PMC2538768%20table%202_files/image006.png" alt="Table 4"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl4/"
target=table>Table 4</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>EGFR
expression as assessed by IHC</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>K-RAS</span></i></b><b><span
lang=EN style='font-size:13.5pt;font-family:"Times New Roman","serif"'> mutation
status of the primary tumours and the corresponding metastases </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Primary and
metastatic tumours were also assessed for <i>K-RAS</i> mutations (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> <i>K-RAS</i> mutations were detected in the primary
tumours of five (20%) patients (nos. 8, 10, 22, 23 and 25) and in the
metastatic tumours of five (20%) patients (nos. 9, 10, 11, 16 and 23),
respectively.</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Two patients (nos. 10 and 23) carried the same <i>K-RAS</i>
mutations in both primary and metastatic tumours (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> One of them (case no. 23) carried the Del746-750 EGFR
mutation in the primary tumour but not in metastasis.</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> This was confirmed
by three independent PCRs from three genomic DNAs extracted from serial
sections of the paraffin blocks. Discordance in <i>K-RAS</i> mutation status
between the primary tumours and the corresponding metastases was observed in
six (24%) patients (McNemar test, <i>P</i>=1) (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl3/"
target=true>Table 3</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Response to
gefitinib according to <i>EGFR</i> and <i>K-RAS</i> mutation status </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Nine patients
received gefitinib as first (nos. 23 and 18), third (nos. 15, 16, 19 20 and 22)
or fourth (nos. 14 and 17) line treatment.</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Three patients received gefitinib
before the biopsy of metachronous metastases (nos. 17, 18 and 20) and six
received gefitinib after the biopsy of metastases (nos. 14, 15, 16, 19, 22 and
23).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Five patients (56%) achieved stable disease and four (44%) progressive
disease (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl2/"
target=true>Table 2</a>).</span><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'> <span style='background:yellow'>All
patients who experienced progressive disease on gefitinib were wild type
regarding the <i>EGFR</i> mutation status in both primary tumours and
metastases (nos. 14, 15, 16, and 22), of these, two patients carried <i>K-RAS</i>
mutations in the primary tumour (no. 22) or metastasis (no. 16).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> All the five
patients with stable disease on gefitinib carried EGFR mutations in their
primary tumours (nos. 17, 18, 19, 20 and 23).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Of these, three patients carried
the well-characterised activating mutations in exon 19 (nos. 18, 20 and 23) and
two carried <i>EGFR</i> mutations of unknown function (nos. 17 and 19).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Patient
nos. 18 and 20 who received gefitinib before metachronous metastasis developed
metastatic tumours, which were either wild type in respect to <i>EGFR</i>
mutation status (no. 18) or had acquired resistance because of the T790M <i>EGFR</i>
mutation (no. 20).</span> <span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'> Patient no. 23, who received gefitinib after metastasis,
carried both <i>EGFR</i> and <i>K-RAS</i> mutations in the primary tumour and
the same <i>K-RAS</i> mutation in metastasis.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>Discussion</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Several studies have shown that
activating <i>EGFR</i> mutations in exons 18, 19 and 21 have been associated
with a 75�95% objective response rate with EGFR TKIs, whereas the <i>K-RAS</i> mutations
were associated with a lack of sensitivity to these agents (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib34">Pao <i>et al</i>,
2005</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib38">Sharma
<i>et al</i>, 2007</a>). Epidermal growth factor receptor gene amplification
and protein expression have also been considered as predictors of clinical
benefit with gefitinib (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib20">Hirsch <i>et
al</i>, 2006</a>). However, in clinical studies, a significant percentage of
patients presented clinical benefit when treated with TKIs irrespective of the
expression and mutational status of <i>EGFR</i> (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib38">Sharma <i>et
al</i>, 2007</a>). As, in most studies, <i>EGFR</i> expression and mutations
were determined on the primary tumour, the observed clinical benefit of
patients with wild-type <i>EGFR</i> or the absence of response to TKIs of
patients with <i>EGFR</i> mutations could be due to discordance in the <i>EGFR</i>
mutation status or expression between the primary tumour and the corresponding
metastasis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>This study demonstrated the
existence of a significant discordance of <i>EGFR</i> and <i>K-RAS</i>
mutations occurring in primary tumours and their corresponding metastases in
patients with NSCLC. The discordance in <i>EGFR</i> mutation status was 28% and
that in <i>K-RAS</i> was 24%. Similarly, two other studies in paired NSCLC
tumours showed a discordance of 32 and 27% regarding the <i>EGFR</i> gene copy
number (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib24">Italiano
<i>et al</i>, 2006</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib3">Bozzetti <i>et
al</i>, 2008</a>), whereas another study including six NSCLC patients of Asian
ethnicity reported a 100% concordance in regard to <i>EGFR</i> mutation status
(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib31">Matsumoto
<i>et al</i>, 2006</a>). This discrepancy could be related to the different
sites of the metastatic tumours analysed in this study (five different distant
metastases), whereas in the Matsumoto's <i>et al</i> study, only tumour samples
from brain metastases were included. Diverse sites of metastases in NSCLC
probably represent different clonal outgrowths. Alternatively, we cannot
exclude that the different ethnicity of patients and/or the different types of <i>EGFR</i>
mutations could be the reason for this discrepancy (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib44">Tsao <i>et al</i>,
2006</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib33">Pallis
<i>et al</i>, 2007</a>). In this study including only Caucasian patients, three
classical activating (Del19 and E746V) and four non-classical mutations (T847A,
L692P-V717A, L692P and G857E) were detected, whereas in Matsumoto's <i>et al</i>
study, only classical activating Del19 and L858R mutations were reported.
Concerning the non-classical mutations, it is unlikely to represent PCR artifacts,
as L692F, T847I and G857E <i>EGFR</i> mutations have been previously reported (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib14">Fujimoto <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib45">Tsao <i>et al</i>,
2005</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib22">Hsieh
<i>et al</i>, 2006</a>). Furthermore, the expression of phosphorylated EGFR
(pY1173-EGFR-positive) on tumour cells from metastatic lesions carrying the T847A
and L692P-V717A mutations strongly suggests that the former might be activating
EGFR mutation. The time elapsed between diagnoses of the primary tumour and
corresponding metastasis in patients (nos. 13 and 12) carrying the
abovementioned mutations was 74.5 and 10 months, respectively. Therefore,
acquisition of new mutations may be developed during the evolution of the
metastatic process.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The administration of TKIs could
be an additional explanation of the observed discordance of <i>EGFR</i>
mutations. Three out of 25 patients received gefitinib before the development
of a metachronous metastasis, whereas none of the patients reported in the
Matsumoto's <i>et al</i> study had exposed to TKIs. It is known that NSCLC
patients with EGFR-dependent primary tumours when treated with TKIs can develop
metastases, in which either the EGFR signalling is negated or resistance is
acquired due to secondary <i>EGFR</i> mutations like T790M or MET amplification
(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib10">Daneshmand
<i>et al</i>, 2003</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib16">Gazdar and
Minna, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib13">Engelman <i>et
al</i>, 2007</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib28">Lutterbach <i>et
al</i>, 2007</a>). It is interesting to note that in patients who had not been
exposed to TKIs before biopsy of metastatic lesions, a 18% (4 out of 22
patients) discordance was observed between primary tumours and related
metastases. However, a final explanation of the observed discordance, which
cannot be excluded, concerns the low-frequency intratumoral heterogeneity for
the occurrence of <i>EGFR</i> mutations (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib37">Sakurada <i>et
al</i>, 2008</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Our findings concerning the <i>K-RAS</i>
mutation status are in agreement with a previous study demonstrating that the <i>K-RAS</i>
mutational status of the primary tumour does not always predict the status of
bone metastasis in NSCLC (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib1">Badalian <i>et
al</i>, 2007</a>). A similar phenomenon was also reported in patients with
colorectal cancer (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib43">Tortola <i>et
al</i>, 2001</a>). Although <i>K-RAS</i> mutations seem to be associated with
the early development of NSCLC, it cannot be excluded that <i>K-RAS</i>
mutations are lost later during tumour progression (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib4">Burmer and
Loeb, 1989</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib26">Li <i>et al</i>,
1994</a>). This may, in part, explain the discordance in the <i>K-RAS</i> mutation
status between primary tumours and metachronous metastases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Another possibility for the
observed discordance in the <i>EGFR</i> and <i>K-RAS</i> mutation status could
be related to the administered chemotherapy. However, as shown in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/table/tbl1/"
target=true>Table 1</a>, among the 10 patients who had not received any
treatment before the mutation analysis of the metastatic lesions, 5 developed
metastases with different mutation status from that of the corresponding
primary tumours. Thus, although tumour clone selection through the various
treatments could be an explanation for the different molecular pattern in the
primary tumour and metastatic site, our findings suggest that the metastasis
genotype could be different from that of the corresponding primary tumour
irrespectively of administered chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Previous studies have shown that <i>EGFR</i>
and <i>K-RAS</i> mutations are mutually exclusive, suggesting the presence of
different pathways of lung carcinogenesis. However, as previously reported, our
data show that <i>K-RAS</i> mutation may coexist with <i>EGFR</i> mutation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib14">Fujimoto <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib18">Han <i>et al</i>,
2006</a>). Among the five patients with <i>EGFR</i> mutations in primary
tumours, one patient concomitantly had <i>K-RAS</i> mutation (G12C with
deletion in exon 19). In the metachronous metastasis, only the <i>K-RAS</i>
mutation was retained. This patient received gefitinib after the biopsy of
metastatic lesion and had stable disease lasting for 3.5 months. The limited
duration of response is compatible with the knowledge that the presence of <i>K-RAS</i>
mutations is associated with resistance to TKIs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In this study, the expression of
pY1173-EGFR was different between primary tumours and corresponding metastases
in eight (50%) patients, whereas EGFR expression was discordant in two (10%)
patients. The apparent lack of correlation between EGFR and p-EGFR expression
has been previously reported and could be due to the different scoring systems
and different sensitivities of antibodies used to evaluate the EGFR and p-EGFR
expressions (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib17">Han <i>et al</i>,
2005</a>). It is well known that overexpression of <i>EGFR</i> is associated
with Tyr phosphorylation of the receptor proteins and that mutations in the
kinase domain may cause constitutive phosphorylation of EGFR (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib6">Chen <i>et al</i>,
2006</a>). However, biochemical studies have shown that variable
phosphorylation rates were associated with different tyrosine phosphorylation
sites in the receptor; G719S mutant receptor had less EGF-induced
phosphorylation at Y845, Y992, Y1068 and Y1173 than did wild-type EGFR, whereas
L858R mutant receptor preferentially phosphorylated at the Y1068 but not at
Y1173 (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib39">Sordella
<i>et al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib6">Chen <i>et al</i>,
2006</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib27">Liu
<i>et al</i>, 2007</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Clinical investigations suggested
a correlation between a high <i>EGFR</i> gene copy number and <i>EGFR</i>
mutations (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib5">Cappuzzo
<i>et al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib40">Takano <i>et
al</i>, 2005</a>). Our study failed to demonstrate such a correlation probably
due to limited number of cases analysed. Evaluable paired tissue specimens for
fluorescence <i>in situ</i> hybridisation analysis were available for eight
patients. Among them, two (nos 13 and 19) patients presented different <i>EGFR</i>
mutation status in the primary tumours and corresponding metastases; however,
these two patients harbour non-classical <i>EGFR</i> mutations (T847A and
G857E) and did not show different <i>EGFR</i> amplification patterns between
paired samples. On the basis of these findings, at the present time, we
consider that only the genetic differences unequivocally distinguish
EGFR-dependent tumours, which are likely to be sensitive to TKIs from the
tumours that could be resistant to these agents (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/#bib35">Papadopoulos <i>et
al</i>, 2006</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In conclusion, our findings
indicate a substantial discordance of <i>EGFR</i> and <i>K-RAS</i> mutations
between the primary tumours and the corresponding metastases in NSCLC and
underline the need to consider the genotype of both primary and metastatic
tumours for selecting patients who will respond to therapy with TKIs.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>Acknowledgments</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>This study was supported by a
research grant from the Cretan Association for Biomedical Research (CABR).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538768/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase'>References</span></b></p>

</div>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Badalian G, Barbai T, Raso
     E, Derecskei K, Szendroi M, Timar J. Phenotype of bone metastases of
     non-small cell lung cancer: epidermal growth factor receptor expression
     and K-RAS mutational status. Pathol Oncol Res. 2007;13:99�104. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17607370" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Bernards R, Weinberg RA. A
     progression puzzle. Nature. 2002;418:823. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12192390" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Bozzetti C, Tiseo M, Lagrasta
     C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, Rusca M,
     Carbognani P, Majori M, Franciosi V, Rindi G, Ardizzoni A. Comparison
     between epidermal growth factor receptor (EGFR) gene expression in primary
     non-small cell lung cancer (NSCLC) and in fine-needle aspirates from
     distant metastatic sites. J Thorac Oncol. 2008;3:18�22. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18166836" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Burmer GC, Loeb LA.
     Mutations in the KRAS2 oncogene during progressive stages of human colon
     carcinoma. Proc Natl Acad Sci USA. 1989;86:2403�2407. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC286921/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/2648401"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cappuzzo F, Hirsch FR, Rossi
     E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K,
     Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A,
     Tonato M, Franklin WA, Crino L, Bunn PA, Jr, Varella-Garcia M. Epidermal
     growth factor receptor gene and protein and gefitinib sensitivity in
     non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643�655. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15870435" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Chen YR, Fu YN, Lin CH, Yang
     ST, Hu SF, Chen YT, Tsai SF, Huang SF. Distinctive activation patterns in
     constitutively active and gefitinib-sensitive EGFR mutants. Oncogene.
     2006;25:1205�1215. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16205628"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Chou TY, Chiu CH, Li LH, Hsiao
     CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM. Mutation in
     the tyrosine kinase domain of epidermal growth factor receptor is a
     predictive and prognostic factor for gefitinib treatment in patients with
     non-small cell lung cancer. Clin Cancer Res. 2005;11:3750�3757. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15897572" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cortas T, Eisenberg R, Fu P,
     Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as
     prognostic markers in resected non-small cell lung cancer. Lung Cancer.
     2007;55:349�355. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17161498"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Dacic S, Flanagan M, Cieply
     K, Ramalingam S, Luketich J, Belani C, Yousem SA. Significance of EGFR
     protein expression and gene amplification in non-small cell lung
     carcinoma. Am J Clin Pathol. 2006;125:860�865. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16690485" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Daneshmand M, Parolin DA,
     Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WH, Jr, Matthews S,
     Seymour L, Lorimer IA. A pharmacodynamic study of the epidermal growth
     factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal
     cancer patients. Clin Cancer Res. 2003;9:2457�2464. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12855618" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Dziadziuszko R, Witta SE,
     Cappuzzo F, Park S, Tanaka K, Danenberg PV, Baron AE, Crino L, Franklin
     WA, Bunn PA, Jr, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth
     factor receptor messenger RNA expression, gene dosage, and gefitinib
     sensitivity in non-small cell lung cancer. Clin Cancer Res.
     2006;12:3078�3084. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16707605"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Endo K, Sasaki H, Yano M,
     Kobayashi Y, Yukiue H, Haneda H, Suzuki E, Kawano O, Fujii Y. Evaluation
     of the epidermal growth factor receptor gene mutation and copy number in
     non-small cell lung cancer with gefitinib therapy. Oncol Rep.
     2006;16:533�541. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16865253"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Engelman JA, Zejnullahu K,
     Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X,
     Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C,
     Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib
     resistance in lung cancer by activating ERBB3 signaling. Science.
     2007;316:1039�1043. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17463250"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Fujimoto N, Wislez M, Zhang
     J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato
     M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill
     DW, Wistuba II, Kurie JM. High expression of ErbB family members and their
     ligands in lung adenocarcinomas that are sensitive to inhibition of
     epidermal growth factor receptor. Cancer Res. 2005;65:11478�11485. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16357156" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Garnis C, Lockwood WW, Vucic
     E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL. High
     resolution analysis of non-small cell lung cancer cell lines by whole
     genome tiling path array CGH. Int J Cancer. 2006;118:1556�1564. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16187286" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Gazdar AF, Minna JD. Inhibition
     of EGFR signaling: all mutations are not created equal. PLoS Med.
     2005;2:e377. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1479603/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16288556"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Han SW, Hwang PG, Chung DH,
     Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. Epidermal growth
     factor receptor (EGFR) downstream molecules as response predictive markers
     for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell
     lung cancer. Int J Cancer. 2005;113:109�115. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15386420" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Han SW, Kim TY, Jeon YK,
     Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
     Optimization of patient selection for gefitinib in non-small cell lung
     cancer by combined analysis of epidermal growth factor receptor mutation,
     K-ras mutation, and Akt phosphorylation. Clin Cancer Res.
     2006;12:2538�2544. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16638863"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hirsch FR. EGFR: a
     prognostic and/or a predictive marker. J Thorac Oncol. 2006;1:395�397. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17409888" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hirsch FR, Varella-Garcia M,
     Bunn PA, Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P,
     Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G,
     Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors
     of outcome with gefitinib in a phase III placebo-controlled study in
     advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5034�5042. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17075123" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hirsch FR, Varella-Garcia M,
     McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Jr, Franklin WA, Crowley
     J, Gandara DR. Increased epidermal growth factor receptor gene copy number
     detected by fluorescence <i>in situ</i> hybridization associates with
     increased sensitivity to gefitinib in patients with bronchioloalveolar
     carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol.
     2005;23:6838�6845. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15998906"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hsieh MH, Fang YF, Chang WC,
     Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen
     YT, Hsi BL, Tsai SF, Huang SF. Complex mutation patterns of epidermal
     growth factor receptor gene associated with variable responses to
     gefitinib treatment in patients with non-small cell lung cancer. Lung
     Cancer. 2006;53 3:311�322. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16870303" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hynes RO. Metastatic
     potential: generic predisposition of the primary tumor or rare, metastatic
     variants or both. Cell. 2003;113:821�823. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12837240" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Italiano A, Vandenbos FB,
     Otto J, Mouroux J, Fontaine D, Marcy PY, Cardot N, Thyss A, Pedeutour F.
     Comparison of the epidermal growth factor receptor gene and protein in
     primary non-small-cell-lung cancer and metastatic sites: implications for
     treatment with EGFR-inhibitors. Ann Oncol. 2006;17:981�985. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16524970" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Koutsopoulos AV, Mavroudis
     D, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS,
     Georgoulias V, Stathopoulos EN. Simultaneous expression of c-erbB-1,
     c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung
     carcinomas: correlation with clinical outcome. Lung Cancer. 2007;57
     2:193�200. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17442448"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Li S, Rosell R, Urban A,
     Font A, Ariza A, Armengol P, Abad A, Navas JJ, Monzo M. K-ras gene point
     mutation: a stable tumor marker in non-small cell lung carcinoma. Lung
     Cancer. 1994;11:19�27. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/8081702" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Liu Y, Purvis J, Shih A,
     Weinstein J, Agrawal N, Radhakrishnan R. A multiscale computational
     approach to dissect early events in the Erb family receptor mediated
     activation, differential signaling, and relevance to oncogenic
     transformations. Ann Biomed Eng. 2007;35:1012�1025. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021414/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17273938"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Lutterbach B, Zeng Q, Davis
     LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. Lung cancer cell lines
     harboring MET gene amplification are dependent on Met for growth and
     survival. Cancer Res. 2007;67:2081�2088. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17332337" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Lynch TJ, Bell DW, Sordella
     R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM,
     Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.
     Activating mutations in the epidermal growth factor receptor underlying
     responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med.
     2004;350:2129�2139. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15118073"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Marsit CJ, Hasegawa M, Hirao
     T, Kim DH, Aldape K, Hinds PW, Wiencke JK, Nelson HH, Kelsey KT. Loss of
     heterozygosity of chromosome 3p21 is associated with mutant TP53 and
     better patient survival in non-small-cell lung cancer. Cancer Res.
     2004;64:8702�8707. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15574780"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Matsumoto S, Takahashi K,
     Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J. Frequent
     EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer.
     2006;119:1491�1494. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16642476"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Paez JG, Janne PA, Lee JC,
     Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ,
     Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.
     EGFR mutations in lung cancer: correlation with clinical response to
     gefitinib therapy. Science. 2004;304:1497�1500. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15118125" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Pallis AG, Voutsina A,
     Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki
     M, Stathopoulos E, Mavroudis D, Georgoulias V. �Classical' but not �other'
     mutations of EGFR kinase domain are associated with clinical outcome in
     gefitinib-treated patients with non-small cell lung cancer. Br J Cancer.
     2007;97:1560�1566. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360265/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18000506"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Pao W, Wang TY, Riely GJ,
     Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE.
     KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib
     or erlotinib. PLoS Med. 2005;2:e17. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC545207/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15696205"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Papadopoulos N, Kinzler KW,
     Vogelstein B. The role of companion diagnostics in the development and use
     of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24:985�995. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16900147" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Perez-Soler R, Chachoua A,
     Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM,
     Santabarbara P, Bonomi P. Determinants of tumor response and survival with
     erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238�3247.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15310767" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Sakurada A, Lara-Guerra H,
     Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung
     adenocarcinoma. J Thorac Oncol. 2008;3:527�529. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18449007" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Sharma SV, Bell DW,
     Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung
     cancer. Nat Rev Cancer. 2007;7:169�181. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17318210" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Sordella R, Bell DW, Haber
     DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer
     activate anti-apoptotic pathways. Science. 2004;305:1163�1167. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15284455" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Takano T, Ohe Y, Sakamoto H,
     Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine
     I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Epidermal growth
     factor receptor gene mutations and increased copy numbers predict
     gefitinib sensitivity in patients with recurrent non-small-cell lung
     cancer. J Clin Oncol. 2005;23:6829�6837. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15998907" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Taron M, Ichinose Y, Rosell
     R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C,
     Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran
     T. Activating mutations in the tyrosine kinase domain of the epidermal
     growth factor receptor are associated with improved survival in
     gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res.
     2005;11:5878�5885. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16115929"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Tokumo M, Toyooka S, Kiura
     K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K,
     Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N. The
     relationship between epidermal growth factor receptor mutations and
     clinicopathologic features in non-small cell lung cancers. Clin Cancer
     Res. 2005;11:1167�1173. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15709185" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Tortola S, Steinert R,
     Hantschick M, Peinado MA, Gastinger I, Stosiek P, Lippert H, Schlegel W,
     Reymond MA. Discordance between K-ras mutations in bone marrow
     micrometastases and the primary tumor in colorectal cancer. J Clin Oncol.
     2001;19:2837�2843. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387355"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Tsao AS, Tang XM, Sabloff B,
     Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I.
     Clinicopathologic characteristics of the EGFR gene mutation in non-small
     cell lung cancer. J Thorac Oncol. 2006;1:231�239. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17409862" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Tsao MS, Sakurada A, Cutz
     JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand
     M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L,
     Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer �
     molecular and clinical predictors of outcome. N Engl J Med.
     2005;353:133�144. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16014883"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>van �t Veer LJ, Dai H, van
     de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton
     MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS,
     Bernards R, Friend SH. Gene expression profiling predicts clinical outcome
     of breast cancer. Nature. 2002;415:530�536. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11823860" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>van Zandwijk N, Mathy A,
     Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof
     P. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase
     inhibitors: retro- and prospective observations in non-small-cell lung
     cancer. Ann Oncol. 2007;18:99�103. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/17060486" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Van't Veer LJ, Weigelt B.
     Road map to metastasis. Nat Med. 2003;9:999�1000. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12894162" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Yokota J, Kohno T. Molecular
     footprints of human lung cancer progression. Cancer Sci. 2004;95:197�204.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15016317" target="pmc_ext">PubMed</a>]</span></li>
</ul>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
